25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils. (December 2022) - Ferrara, R.; Lo Russo, G.; Ciniselli, C.M.; Bassani, B.; Calareso, G.; Duroni, V.; Di Gregorio, S.; Proto, C.; Prelaj, A.; De Toma, A.; Occhipinti, M.; Brambilla, M.; et al.